5,848 reports of this reaction
4.6% of all RUXOLITINIB reports
#3 most reported adverse reaction
FATIGUE is the #3 most commonly reported adverse reaction for RUXOLITINIB, manufactured by Incyte Corporation. There are 5,848 FDA adverse event reports linking RUXOLITINIB to FATIGUE. This represents approximately 4.6% of all 126,373 adverse event reports for this drug.
RUXOLITINIB has an overall safety score of 85 out of 100. Patients taking RUXOLITINIB who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among RUXOLITINIB users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for RUXOLITINIB:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 5,848 FDA reports for RUXOLITINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 4.6% of all adverse event reports for RUXOLITINIB, making it one of the most commonly reported side effect.
If you experience fatigue while taking RUXOLITINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.